Looking into the Differences in Approaching TCEs for Autoimmune vs Oncology Indications
Time: 1:00 pm
day: Day 1
Details:
- Comparing the mechanistic and translational differences in T-cell engager design for autoimmune diseases versus oncology, including target selection and immune activation thresholds
- Evaluating safety considerations, balancing immune activation and toxicity, and lessons learned from cytokine release syndrome management in both therapeutic areas
- Exploring emerging strategies to tailor T-cell engagers for autoimmune indications, including selective T-cell modulation, tissue-restricted targeting, and dose optimization
